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Ovarian cancer is the third most common gynecologic malignancy worldwide but
accounts for the highest mortality rate among these cancers. A stepwise approach
to assessment, diagnosis, and treatment is vital to appropriate management of
this disease process. An integrated approach with gynecologic oncologists as well
as medical oncologists, pathologists, and radiologists is of paramount importance
to improving outcomes. Surgical cytoreduction to R0 is the mainstay of treatment,
followed by adjuvant chemotherapy. Genetic testing for gene mutations that affect
treatment is the standard of care for all women with epithelial ovarian cancer. Nearly
all women will have a recurrence, and the treatment of recurrent ovarian cancer
continues to be nuanced and requires extensive review of up to date modalities
that balance efficacy with the patient’s quality of life. Maintenance therapy with poly
ADP-ribose polymerase inhibitors, bevacizumab, and/or drugs targeting homologous
recombination deficiency is becoming more widely used in the treatment of ovarian
cancer, and the advancement of immunotherapy is further revolutionizing treatment
targets.
Introduction
Ovarian cancer is the most lethal of the gynecologic
malignancies. Despite other cancers such as
endometrial cancer having higher rates of incidence,
ovarian cancer mortality rates continue to be high.1
Ongoing work is important to screen and diagnose
epithelial ovarian cancer (EOC) earlier, but many
trials have failed to find an appropriate modality or
biomarker to predict which women in the general
population will develop this disease. As a result, most
cases (>80%) of EOC are diagnosed at an advanced
stage when tumor has spread to the peritoneal cavity
and upper abdominal organs.2 This substantially
reduces the ability to cure this malignancy, given that
five year survival rates plummet after the disease has
escaped the pelvic cavity.
Despite these statistics, treatment options tested
in the past five years have revolutionized the
management of EOC and more targeted therapies
are on the horizon (fig 1). The treatment landscape
for ovarian cancer has also begun to experience
innovation in biomarker development similar to those
for lung and colon cancer. This includes identification
of the breast cancer BRCA gene and tumors that
exhibit homologous recombination deficiency (HRD).
New treatments in the sphere of poly ADP-ribose
polymerase (PARP) inhibitors,3-6 immunotherapy,
and heated intraperitoneal chemotherapy (HIPEC)7
have the ability to transform the treatment paradigm
for ovarian cancer, substantially increasing survival
for what was uniformly thought to be a fatal cancer.
This review is targeted toward gynecologic/
surgical oncologists and medical oncologists who
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are involved in the multidisciplinary approach to
ovarian cancer. We will review the epidemiology and
risk factors for the development of this disease, as
well as the surgical techniques vital to its treatment.
Adjuvant therapies in the form of chemotherapy will
be reviewed in the primary and recurrent/refractory
settings. The latest controversies and avenues for
future treatments and therapies are discussed.
Sources and selection criteria
We selected references for this review to reflect
landmark articles that have shaped diagnosis and
management of ovarian cancer over the past 20
years. We searched PubMed and Embase between
2000 and 2020 and selected peer reviewed articles in
the English language by using the following search
terms: ovarian cancer, neoadjuvant chemotherapy,
primary cytoreductive surgery, lymphadenectomy,
secondary cytoreductive surgery, hyperthermic
intraperitoneal
chemotherapy,
intraperitoneal
chemotherapy, adjuvant chemotherapy, main
tenance therapy, recurrence, platinum sensitive
recurrence, platinum resistant recurrence, immuno
therapy, PARP inhibitors, bevacizumab, and chimeric
antigen receptor therapy (CAR-T). We also identified
references from relevant review articles, as well as
from the similar items section of PubMed and the
National Comprehensive Cancer Network (NCCN)
and European Society for Medical Oncology Clinical
Practice guidelines.8 9 We screened and reviewed
more than 200 articles in the preparation of this
manuscript. We prioritized publications within the
past decade but also included more historic articles
1
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that were considered landmark trials that changed
the treatment paradigm of ovarian cancer. We
prioritized randomized controlled trials, systematic
reviews, meta-analyses, observational studies,
Society of Gynecologic Oncology (SGO) consensus
statements, and systematic reviews published within
the past 10 years. We excluded articles published in
non-peer reviewed journals, case reports, and case
series.
Epidemiology and risk factors
Epithelial ovarian cancer represents the most lethal
of the gynecologic malignancies. In 2020 more than
300 000 new cases of EOC are expected worldwide,
with more than 190 000 deaths.1 10 The median age
at diagnosis is 63 years, and more than 70% of cases
of EOC are diagnosed at advanced stages with five
year survival rates approximating 48%.2
The lifetime risk of developing EOC is 1.3%, but
it is as high as 40-45% for women with a BRCA1
mutation and 15-20% for BRCA2 carriers.11 Risk
factors for EOC include increasing age, infertility,
endometriosis, polycystic ovarian syndrome, use of
an intrauterine device, and cigarette smoking (for
mucinous carcinomas). An estimated 18% of cases
of EOC are associated with a germline mutation12;

most of these are attributable to BRCA1 and BRCA2,
but they also include other genes in the homologous
recombination pathway (for example, TP53, ATM,
MRE11, RAD51, H2AX, PALB2, RPA, BPIP1, BARD1,
and RAD52)12-14 and mismatch repair genes.15-17
The Cancer Genome Atlas Research Network
evaluated 316 stage II through IV high grade
serous ovarian cancer (HGSOC) specimens and
reported that 3% of the cases showed somatic
BRCA1/2 mutations.18 Therefore, genetic screening
is recommended in all patients newly diagnosed as
having EOC.
Histological subtypes
The World Health Organization classification of tuboovarian tumors includes common epithelial tumors,
sex cord stromal tumors, germ cell tumors, soft tissue
tumors, unclassified type, and metastatic secondary
tumors (5-6% of adnexal masses are metastases
from breast, gastrointestinal tract, or urinary tract).
Given that HGSOC is the most common histological
subtype, accounting for 75% of all EOCs, we will
focus on this specific subgroup. Table 1 describes the
other histology subtypes, including endometrioid,
clear cell, low grade serous, and mucinous, in more
detail.
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Fig 1 | Evaluation and management of epithelial ovarian cancer. BSO=bilateral salpingo-oophorectomy; CA-125=cancer antigen 125; CBC=complete
blood count; CT=computed tomography; CXR=chest ragiograph; LFT=liver function test; MRI=magnetic resonance imaging; PARPi=poly ADP-ribose
polymerase inhibitor; TAH=total abdominal hysterectomy; USO=unilateral salpingo-oophorectomy.
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Surgery for ovarian cancer
Neoadjuvant chemotherapy versus primary
debulking
Primary cytoreductive surgery (PCS) followed by
platinum based chemotherapy remains the standard
treatment for patients with advanced stage EOC.
Thus, all women with suspected stage IIIC or IV EOC
should be evaluated by a gynecologic oncologist
before treatment is started, to determine whether they
are candidates for PCS.19 Neoadjuvant chemotherapy
may be considered for patients with bulky stage III
or IV disease whose tumors are deemed unlikely
to be completely cytoreduced to no gross residual
disease (R0) or for patients who are poor surgical
candidates. Although the choice between PCS and
neoadjuvant chemotherapy remains controversial,
the SGO and American Society of Clinical Oncology
(ASCO) clinical practice guidelines state that
for those women who have a high likelihood of
achieving a cytoreduction to less than 1 cm (ideally
to no visible disease) with acceptable morbidity, PCS
is recommended over neoadjuvant chemotherapy
(evidence quality: intermediate; strength of
recommendation: moderate).19 Theoretical advances
in surgical cytoreduction pertain to removal of large
and/or poorly vascularized tumors, thus eliminating
pharmacologic sanctuaries and allowing for optimal
killing of the cells of the better perfused small
residual tumors that have higher growth fractions;
host immunocompetence is enhanced by removal
of large tumor bulk and prevention of resistance to
chemotherapy.20 21 A primary clinical evaluation
should include a computed tomography scan of the
chest, abdomen, and pelvis to evaluate the extent
of disease and the feasibility of surgical resection.
In exceptional cases when a biopsy is not feasible,
cytological evaluation combined with a serum cancer
antigen 125 (CA-125) to carcinoembryonic antigen
ratio above 25 is acceptable to confirm the primary
diagnosis and exclude a non-gynecologic cancer.19
Should neoadjuvant chemotherapy be deemed
the optimal management strategy, histological
confirmation of EOC by biopsy is preferred over
fine needle aspiration or paracentesis, before
administration of neoadjuvant chemotherapy.
As our population is aging, a careful assessment of
operability based on the patient’s age, functional and

instrumental activities of daily living, performance
status, comorbidities, and nutritional status is critical
for preoperative planning, as these factors have
been shown to predict postoperative complications,
extended hospital stay, and six month mortality in
older patients undergoing cancer surgery.8 22-24 The
American College of Surgeons and the American
Geriatrics Society have provided general guidelines
for the preoperative assessment of older patients
undergoing surgery.25 Patients 75 years of age or
older who have at least one comorbidity have a 30
day postoperative mortality of greater than 10% after
planned PCS for stage III EOC.26
A laparoscopic surgical assessment using the
Fagotti scoring system has been studied and
externally validated to determine the feasibility of PCS
to no gross residual disease.27 28 Seven parameters
are included in this scoring system—peritoneal
carcinomatosis, diaphragmatic disease, mesenteric
disease, omental disease, bowel infiltration, sto
mach infiltration, and liver metastasis. Mesenteric
retraction was the most difficult to assess (75.2%)
by laparoscopy, although stomach infiltration had
the poorest negative predictive value (71.6%) and
accuracy (77.3%). A review on predictors of optimal
cytoreduction in patients with newly diagnosed
advanced stage EOC commented that standard use
of the Fagotti score should be implemented across
different centers, with a predictive index value of
8 or greater shown to have the best prediction of
suboptimal cytoreduction.29
Four phase III trials have evaluated whether
neoadjuvant chemotherapy followed by interval
cytoreductive surgery (ICS) is effective and safe
compared with PCS followed by platinum based
chemotherapy (table 2).31-35 Results from these trials
have formed the basis of clinical practice guidelines
on neoadjuvant chemotherapy for newly diagnosed,
advanced EOC set forth by the SGO and ASCO.30 In
each of these trials, neoadjuvant chemotherapy
consisted of three to four cycles of carboplatin and
paclitaxel.
Two phase III trials showed non-inferiority of
neoadjuvant chemotherapy with ICS compared
with PCS followed by chemotherapy. The first
was the European Organization for Research and
Treatment of Cancer (EORTC)-55971, a phase III

Table 1 | Histological subtypes of epithelial ovarian cancers and their common characteristics
Characteristics
% of cases
Median age at diagnosis
Tumor marker(s)
Genetic risk factors
Common stage at presentation
Response to platinum based chemotherapy
Common gene mutations

Common immune profile

High grade serous
carcinoma
70
61
CA-125
BRCA1/2
Advanced
Chemo-sensitive
P53; BRCA1/2;
HR defects
P53+; WT1+;
Pax8+; high Ki67

Clear cell carcinoma
12
55
CA-125
HNPCC
Early
Chemo-resistant radiosensitive
PIK3CA; ARD1A;
PTEN; MSI
HNF β+; WT1-; ER-

Endometrioid
carcinoma
11
56
CA-125
HNPCC/BRCA
Early
Chemo-sensitive
CTNNB1; ARID1A;
PTEN; MSI
ER+; Pax8+; vimentin+
WT1-; P53 wild-type

Mucinous
carcinoma
3
53
CEA; CA19-9
Not known
Early
Chemo-resistant
KRAS; HER2;
CDKN2A
CK20+; Cdx2+;
CK7+; ER-; WT1-

Low grade serous
carcinoma
3
43
CA-125
Serous borderline tumor
Advanced
Chemo-resistant
BRAF; KRAS; NRAS;
ERBB2; PIK3CA
WT1+; Pax8+;
P53 wild-type; low Ki67

BRCA1/2=breast cancer susceptibility gene 1/2; CA-125=cancer antigen 125; CEA=carcinoembryonic antigen; ER=estrogen receptor; HNPCC=hereditary non-polyposis colorectal cancer;
HR=homologous recombination; MSI=microsatellite instability; PTEN=phosphatase and tensin homolog; STIC=serous tubal intraepithelial carcinoma; TP53=tumor protein p53.
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international trial of 670 women with stage IIIC/IV
EOC randomized to neoadjuvant chemotherapy with
ICS versus up-front PCS.34 Median overall survival
was equivalent (29 v 30 months for neoadjuvant
chemotherapy v PCS), but patients who received
neoadjuvant chemotherapy had fewer surgical
complications. In the CHORUS trial, 550 patients
with clinical stage III-IV disease were randomized
to PCS followed by six cycles of chemotherapy or
neoadjuvant chemotherapy.33 In intention to treat
analysis, median overall survival for the PCS group
was 22.8 months compared with 24.5 months for
those undergoing neoadjuvant chemotherapy.
Later, a pooled analysis of individual patient data
from the EORTC 55971 and CHORUS trials showed
improved survival for patients with stage IV disease
who received neoadjuvant chemotherapy followed
by ICS: median overall survival 24.3 months in
the neoadjuvant chemotherapy group versus 21.2
months in the PCS group (hazard ratio 0.76, 95%
confidence interval 0.58 to 1.00; P=0.48) and
median progression-free survival (PFS) 10.6 versus
9.7 months (0.77, 0.59 to 1.00; P=0.049).34
Major criticisms of the EORTC trial relate
to selection bias for patients at high risk that
were not inclusive of all stage III patients and
generalizability of surgical attempt to achieve
R0 resection.34 The largest residual tumor was
reported to be 1 cm or smaller in 41.6% of patients
after PCS and in 80.6% of patients after ICS. As
expected, median overall survival rates varied
by largest residual tumor and treatment arm
(neoadjuvant chemotherapy versus PCS)—overall
survival was 38 versus 45 months for R0, 27
versus 32 months for R1 disease, and 25 versus 20
months for R2 disease. Despite these limitations,
an exploratory analysis of the EORTC data helped
to better identify which subgroups of patients with
stage III-IV EOC benefit most from neoadjuvant
chemotherapy versus PCS.36 Those with stage IIIC
tumors smaller than 4.5 cm benefited more from
PCS, whereas stage IV patients with metastatic
tumors larger than 4.5 cm benefited more from
neoadjuvant chemotherapy.

Importance of optimal (R0) cytoreduction
Irrespective of when surgery is performed—up front
or after neoadjuvant chemotherapy in the primary
setting—the goal remains removal of all visible
tumor. As with PCS, maximal effort should be made
to remove all gross disease in the abdomen, pelvis,
and retroperitoneum. The volume of residual disease
remaining after cytoreductive surgery is one of the
most powerful determinants of survival for patients
with EOC.37-39 One meta-analysis involving 6885
patients with stage III or IV ovarian carcinoma
reported that with each 10% increase in maximal
cytoreduction, a 5.5% increase in median survival
time was seen.39
Neoadjuvant chemotherapy should be considered
when optimal cytoreduction is unlikely or would
be at the cost of high perioperative morbidity
and mortality. In these cases, ICS should be
performed after four cycles or fewer of neoadjuvant
chemotherapy for women who have achieved a
response to chemotherapy or have stable disease.
Another meta-analysis of 835 patients with
advanced stage EOC confirmed previous findings
that increasing percentage maximal cytoreduction
is positively associated with median cohort survival;
however, it also showed that a 4.1 month decrease in
survival is seen for each extra cycle of neoadjuvant
chemotherapy, suggesting that definitive operative
intervention should be undertaken as early in the
treatment course as possible.40 Ultimately, timing
of surgery has not been prospectively evaluated and
should be determined on an individual basis.
Bevacizumab containing regimens for neoadjuvant
chemotherapy should be used with caution
before ICS, given the potential for compromised
postoperative healing. If bevacizumab is used as part
of a neoadjuvant chemotherapy regimen, it should
be withheld from therapy for at least 28 days before
ICS.41
General principles of surgical cytoreduction
Surgical cytoreduction should be done by an
experienced, high volume gynecologic oncologist
(≥10 cases/year) at a high volume hospital (≥20 cases/

Table 2 | Trials studying neoadjuvant chemotherapy versus primary cytoreductive surgery30
Study*
SCORPION31 32

Inclusion criteria
Stage IIIC-IV; Fagotti score 8-12

CHORUS33

Stage III-IV based on imaging or clinical
evidence of pelvic mass with extra pelvic
disease; CA-125/CEA >25
Biopsy proven stage IIIC-IV. In combination with
pelvic mass, presence of metastasis of ≥2cm
outside the pelvis, and CA-125/CEA ≥25
Stage III-IV based on CT, MRI, cytological tests,
CA-125 >200 U/mL, and CEA <20 ng/mL

EORTC 5597134
JCOG060235

Arms (n)
NACT (55) v
PCS (55)
NACT (274) v
PCS (276)

No residual
disease
58% v 46%;
P=0.16
39% v 17%;
P=0.0001

NACT (334) v
PCS (336)

51% v 19%

NACT (152) v
PCS (149)

63% v 30%

Grade 3-4
postoperative
complication†
6% v 53%; P=000001

14% v 24%; P=0.007

Progression-free
survival (months)
–

Overall survival‡
(months)
–

12 v 10.7; HR 0.91
24.1 v 22.6; HR 0.87
(95% CI 0.76 to 1.09) (0.72 to 1.05)

Mortality: 0.7% v
12 v 12; HR 1.01
0.6%; sepsis: 8% v 2%; (0.89 to 1.15)
hemorrhage: 7% v 4%
5% v 15%; P=0.005
-

30 v 29; HR 0.98
(0.84 to 1.13); P=0.01
44.3 v 49.0; HR 1.05
(0.08 to 1.33); P=0.24

CA-125=cancer antigen 125; CEA=carcinoembryonic antigen; CT=computed tomography; HR=hazard ratio; MRI=magnetic resonance imaging; NACT=neoadjuvant chemotherapy; PCS=primary
cytoreductive surgery.
*All were designed as non-inferiority trials except for SCORPION (superiority trial).
†Primary outcome for SCORPION.
‡Primary outcome for CHORUS, EORTC55971, and JCOG0602.
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year).42 A vertical midline abdominal incision should
be used in most patients with suspected malignant
EOC in whom a surgical staging procedure, a PCS, or
an ICS is planned. Interest is growing in conducting a
multicenter surgical trial to investigate the feasibility
and safety of using a minimally invasive ICS for
women who have had a complete response after three
to four cycles of neoadjuvant chemotherapy with a
CA-125 that has normalized.43 44 Given that nearly
75% of patients newly diagnosed as having EOC
present with advanced disease, surgical procedures
that may be considered for optimal cytoreduction
include bowel resection and/or appendectomy, dia
phragm or peritoneal stripping, splenectomy, partial
cystectomy and/or ureteroneocystostomy, partial
hepatectomy, partial gastrectomy, cholecystectomy,
and/or pancreatectomy.
Cytoreductive surgery for patients at stage IV
can be attempted, with 30% achieving optimal
cytoreduction. A retrospective cohort study showed
that survival depends on the location of the stage
IV disease. Those with pleural effusion present had
a median survival of 19 months compared with 12
months if lung metastasis was present, 18 months
for parenchymal liver metastasis, and 26 months for
those with other extraperitoneal sites.40
Removal of lymph nodes for advanced stage disease
has also been studied. Some retrospective studies
have suggested a potential survival benefit from
systematic pelvic and para-aortic lymphadenectomy
in patients with macroscopically resected advanced
EOC, although these studies are inherently flawed by
selection bias.
A landmark randomized international trial studied
427 patients with stage IIB, IIIC, or IV disease, all
of whom had optimal surgery and were randomized
intraoperatively to systematic pelvic and para-aortic
lymphadenectomy versus resection of bulky nodes
only.45 All patients received adjuvant platinum based
chemotherapy. The five year progression-free interval
was 31.2% for the lymphadenectomy group compared
with 21.6% for the control arm, with no difference in
the risk of death. Patients in the lymphadenectomy
group were more likely to need blood transfusions
and had longer surgery and more postoperative
complications. Although highly cited, this study was
criticized for several reasons: participating surgeons
were not required to prove proficiency in performing
a complete lymphadenectomy, thus contributing to
heterogeneity of surgical quality among participating
centers; resection of bulky nodes was permitted in
the no lymphadenectomy arm; and more than two
thirds of included patients had residual postoperative
intra-abdominal disease, which makes interpreting
the potential benefit of lymphadenectomy difficult.
Ultimately, because of these limitations, results of
this trial did not change practice.
Learning from these previous criticisms, the
Lymphadenectomy in Ovarian Neoplasms (LION)
trial emerged.46 This was a randomized controlled
trial of 647 patients intraoperatively randomized

the bmj | BMJ 2020;371:m3773 | doi: 10.1136/bmj.m3773

to either undergo systematic pelvic and para-aortic
lymphadenectomy or not undergo lymphadenectomy
if macroscopic complete resection was achieved
and the patient had normal lymph nodes both
before and during surgery. Median overall survival,
the primary outcome, was 69.2 months in the no
lymphadenectomy group and 65.5 months in the
lymphadenectomy group (hazard ratio 1.06, 0.83
to 1.34; P=0.65). Median PFS was 25.5 months
in both groups, and postoperative morbidity was
higher in the lymphadenectomy group, including
percentage of patients receiving transfusions
(63.7% v 56%; P=0.005), incidence of infections
treated with antibiotics (25.8% v 18.6%; P=0.03),
repeat laparotomy (12.4% v 6.5%; P=0.01), and
mortality within 60 days after surgery (3.1% v
0.9%; P=0.049). Taken together, these data suggest
that patients with advanced EOC with normal
lymph nodes both before and during surgery who
undergo macroscopically complete resection do
not benefit from systematic pelvic and para-aortic
lymphadenectomy.
Hyperthermic intraperitoneal chemotherapy after
cytoreduction
HIPEC with cisplatin (100 mg/m2) can be considered
at the time of interval cytoreductive surgery for
stage III disease (see section below). A phase III
multicenter trial recently published results showing
that the addition of HIPEC as a single administration
of intraperitoneal chemotherapy to ICS improved
recurrence-free survival (RFS) by 3.5 months and
overall survival by 11.8 months compared with
surgery alone, without increasing perioperative
morbidity.7 The trial included 245 patients with stage
III EOC who had at least stable disease after three
cycles of neoadjuvant carboplatin and paclitaxel, who
were randomized at the time of ICS when incomplete
or optimal site of reduction was anticipated. Median
RFS, the primary endpoint, was 10.7 months in the
surgery group and 14.2 months in the surgery plus
HIPEC group. The median overall survival was 33.9
months in the surgery group and 45.7 months in
the surgery plus HIPEC group. The percentage of
patients who had adverse events of grade 3 or 4 was
similar in the two groups (25% in the surgery group
and 27% in the surgery plus HIPEC group; P=0.76).
Furthermore, although the overall percentage of
bowel resections performed was similar in the two
groups (34% for both), the HIPEC arm had a higher
rate of colostomy/ileostomy than the surgery arm
(21/29 (72%) v 13/30 (43%); P=0.04). This higher
rate was attributed to surgeons’ preference, given that
no evidence suggests that HIPEC for ovarian cancer is
associated with higher rates of anastomotic leakage.
This study certainly fills a gap in the literature and
provides another option for management, but HIPEC
has not been widely adopted and should be practiced
at institutions that have expertise in both delivery of
HIPEC and management of complications that may
ensue.
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Primary adjuvant therapy
Adjuvant therapy for early stage ovarian cancer
patients
The decision to recommend adjuvant therapy for
patients with early stage EOC should be individualized
according to histology, risk factors, adequacy of
staging, comorbidities, and likelihood of response
to platinum based chemotherapy. Observation is
recommended for those with optimally staged IA
or IB, grade 1 endometrioid carcinomas and other
histology given that five year survival rates are greater
than 90% with surgical treatment alone.47 48 If
adjuvant therapy is recommended, three to six cycles
are generally recommended.49 50 A retrospective
analysis of GOG157, which compared three versus
six cycles of adjuvant carboplatin and paclitaxel,
showed improved RFS with six cycles among
patients with HGSOC. Among non-serous tumors,
no difference was observed between three and six
cycles. The European Organization for Research
and Treatment of Cancer-Adjuvant Chemotherapy
in Ovarian Neoplasm (EORTC-ACTION) and the
International Collaborative Ovarian Neoplasm
(ICON1) trial were set up as parallel, complementary
randomized trials, which showed that platinum
based adjuvant chemotherapy, compared with
observation, improved overall survival (hazard ratio
0.67, 0.5 to 0.9; P=0.008) and RFS (0.64, 0.5 to 0.82;
P=0.001) among patients with surgically resected
early stage EOC.51 A subgroup analysis, which was
likely to be limited by numbers, of the combined
ICON1/ACTION data within the subcategories of age,
stage, histology, and cell differentiation provided
no evidence that the effect of chemotherapy was
different within any of the subgroups.
Impact of surgical staging was assessable only
in the ACTION trial, although only about a third of
patients were fully staged. After a median followup of 5.5 years, the original ACTION trial results
showed that the benefit of chemotherapy seemed
to be limited to patients with non-optimal staging.
Long term results after a median follow-up of 10.1
years supported most conclusions from the original
analysis, with the exception that overall survival after
optimal surgical staging was improved, even among
patients who received adjuvant chemotherapy
(hazard ratio of death 1.89, 0.99 to 3.60; P=0.05).52
A meta-analysis of all randomized clinical trials
comparing adjuvant chemotherapy with observation
for patients with adequately staged I-II EOC showed
no survival benefit of adjuvant chemotherapy
(hazard ratio 0.91, 0.51 to 1.61).53
Adjuvant therapy for advanced stage ovarian cancer
patients
First line chemotherapy for EOC is a platinum
agent with a taxane. GOG111, a landmark phase
III trial, showed improved overall survival with the
combination of cisplatin and paclitaxel compared
with cisplatin and cyclophosphamide.54 Other
landmark trials that answered important clinical
questions have shown that: carboplatin is as effective
6

as cisplatin and better tolerated55; weekly dosedense chemotherapy with carboplatin and paclitaxel
compared with standard three weekly chemotherapy
does not improve long term PFS56; adding a third
drug to a doublet chemotherapy has no additional
benefit57-59; extended cycles of chemotherapy do not
confer survival benefit60; and, likewise, docetaxelcarboplatin seems to provides similar PFS and
response to paclitaxel-carboplatin at the expense of
more grade 3-4 neutropenia (94% v 84%; difference
11%, 95% confidence interval 7% to 14%; P<0.001)
but improved grade 2 or higher neurotoxicity (11% v
30%; 15% to 24%; P<0.001).61
Intravenous versus intraperitoneal chemotherapy
In women with optimally cytoreduced, ideally
to no gross residual, disease who have not
received neoadjuvant chemotherapy, intravenous
chemotherapy, or a combination of intravenous
and intraperitoneal chemotherapy is a reasonable
option. The appeal of intravenous/intraperitoneal
chemotherapy stems from the need to optimize
penetration of diffusion limited drugs, such as
cisplatin, in a disease that is largely locoregional
and characterized by peritoneal carcinomatosis.
Four landmark trials (table 3) have been published
since 1996,62-65 three showing survival benefit of
intraperitoneal over intravenous chemotherapy,
even among both R1 and R0 groups, and with larger
magnitude of benefit in women who completed
all six cycles and who had a BRCA mutation.66
However, despite the strong rationale and survival
efficacy, intraperitoneal chemotherapy for EOC is
inconsistently used as standard frontline treatment.67
Several barriers affect the acceptance of intra
peritoneal chemotherapy, including catheter related
complications and higher rates of toxicities such
as gastrointestinal adverse events, neutropenia,
thrombocytopenia, and neurotoxicity. Quality of life
was worse for patients treated with intraperitoneal
chemotherapy, although it was comparable one year
after completion except for neuropathy.68
The most recent trial, GOG252,65 was intended
not only to reduce the toxicities of the GOG172
regimen64 but also to incorporate a biologic targeted
therapy, bevacizumab, as a primary therapy and
maintenance, similar to GOG218. It failed to show a
PFS benefit of intraperitoneal chemotherapy (26.8 v
28.7 months) or intraperitoneal cisplatin (26.8 v 27.8
months) compared with intravenous chemotherapy.
One of the major criticisms of this trial was the fact
that bevacizumab was used across all study arms,
perhaps limiting the effect size of intraperitoneal
therapy but, nevertheless, allowing the control arm
to outperform (PFS 23.8 months) historical controls
from GOG172 (18.3 months).
Dose dense chemotherapy
Dose dense intravenous therapy has also been
compared with conventionally dosed intravenous
therapy (every three weeks) as a first line treatment
strategy in EOC with mixed results. Notable trials
doi: 10.1136/bmj.m3773 | BMJ 2020;371:m3773 | the bmj
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include the Japanese GOG3016 trial, which compared
carboplatin and paclitaxel every three weeks
with carboplatin (every three weeks) and weekly
paclitaxel, showing a significant benefit in PFS (28
v 17.5 months; hazard ratio 0.76, 0.62 to 0.91)
and overall survival (median 100.5 v 62 months;
0.79, 0.63 to 0.99) compared with conventional
treatment.69 Although anticipated, the same survival
benefit was not shown in the US. In GOG262, women
with stage II-IV EOC were randomized either to
conventionally dosed carboplatin and paclitaxel
or to dose dense therapy (carboplatin every three
weeks plus weekly paclitaxel). Bevacizumab was
allowed in both arms and administered to 84%
of the study population.70 The primary endpoint,
PFS, was not significantly improved among women
who received weekly paclitaxel compared with a
regimen of treatment every three weeks. However,
in the subgroup of patients who did not receive
bevacizumab, weekly paclitaxel led to a PFS that was
3.9 months longer than that observed with paclitaxel
administered every three weeks (14.2 v 10.3 months;
hazard ratio 0.62, 0.40 to 0.95; P=0.03).
ICON8 involved similar study arms, comparing
carboplatin and paclitaxel every three weeks
(control, arm 1) versus either carboplatin (AUC 5 or
6) every three weeks and dose dense paclitaxel (80
mg/m2 weekly) (arm 2) or weekly carboplatin (AUC
2) plus paclitaxel (80 mg/m2) (arm 3).71 In this phase
III trial involving 1566 women with IC-IV EOC, no
significant PFS increase was observed with either
weekly regimen (24.4 months control versus 24.9
arm 2 versus 25.3 arm 3). Grade 3-4 toxicities were
higher with the dose dense arms (42% v 62% v 53%).
Chemotherapy considerations for older patients
Although carboplatin as a single agent has been
advocated as a less toxic option, particularly in frail
or elderly patients, a randomized trial of patients
aged 70 years or older with stage III/IV EOC and

determined by geriatric assessment to be vulnerable
showed worse survival outcomes with single
agent carboplatin compared with carboplatin and
paclitaxel every three weeks or weekly.72 This led to
premature closure of the trial. GOG273 studied the
same age group of women (≥70 years) with newly
diagnosed stage III/IV EOC who underwent adjuvant
chemotherapy according to the physician’s choice of
either single agent carboplatin (AUC 5), carboplatin
(AUC 5) plus paclitaxel (135 mg/m2) every three
weeks, or carboplatin (AUC 5) plus weekly paclitaxel
(60 mg/m2). Although the trial is still ongoing,
the authors reported their primary results, which
showed that the instrumental activities of daily living
score could predict the completion of four cycles of
chemotherapy.73
A modified dose dense regimen (carboplatin
(AUC 2) plus paclitaxel (60 mg/m2) every week for
18 weeks) studied in the MITO7 phase III trial, was
shown to offer better tolerability than conventional
dosing and is often considered for medically frail
patients.74 It was associated with decreased grade
3-4 neutropenia (42% v 50%), febrile neutropenia
(0.5% v 3%), grade 3-4 thrombocytopenia (1% v
7%), and grade 2 or worse neuropathy (6% v 17%).
Maintenance after primary adjuvant therapy
Paclitaxel
The role for maintenance therapy is supported by
GOG178, a phase III trial comparing three versus 12
months of paclitaxel 175 mg/m2 every four weeks for
12 cycles after completion of six cycles of platinum/
paclitaxel with a clinical complete response among
patients with stage III-IV EOC.75 This study closed
early after 50% enrollment and an interim analysis
that showed an improved PFS favoring 12 cycles
(28 v 21 months; hazard ratio 2.31, 1.08 to 4.94;
P=0.002). However, a follow-up study showed a
PFS of 22 versus 14 months with no overall survival
benefit.76 As expected, the only major difference with

Table 3 | GOG trials
Progression-free survival
Study
GOG
10462

GOG
11463
GOG
17264
GOG
25265

Study groups
Cisplatin 100 mg/m2 IV; cyclophosphamide 600 mg/m2
IV; Q3 wks × 6 cycles
Cisplatin 100 mg/m2 IP; cyclophosphamide IV;
Q3 wks × 6 cycles
Cisplatin 100 mg/m2 IV; cyclophosphamide 60 mg/m2 IV;
Q3 wks × 6 cycles
Carboplatin (AUC 9) IV every 4 wks × 2; D1 taxol 135 mg/m2
(24 h) IV; D2 cisplatin 100 mg/m2 IP Q3 wks × 6
D1 taxol 135 mg/m2 (24 h); D2 cisplatin 100 mg/m2 IV
D1 taxol 135 mg/m2 (24 h); D2 cisplatin 75 mg/m2 IV;
D8 taxol 60 mg/m2 IP
Arm 1: taxol 80 mg/m2 weekly IV; carboplatin AUC 6 IV;
bev 15 mg/kg IV; bev maintenance × 15 cycles
Arm 2: taxol 80 mg/m2 weekly IV; carboplatin AUC 6 IP;
bev 15 mg/kg IV; bev maintenance × 15 cycles
Arm 3: D1 taxol 135 mg/m2 IV (24 h); D2 cisplatin 75 mg/m2
IP; D8 taxol 60 mg/m2 IP; bev 15 mg/kg IV; bev maintenance
× 15 cycles

Length
(months)
NR

Effect size
(95% CI)
NR

Overall survival*
P value
NR

NR
22.2

RR 0.78 (0.66 to 0.94)

0.01

P value
0.02

RR 0.81 (0.65 to 1.00)

0.05

49.7
65.6

RR 0.75 (0.58 to 0.97)

0.03

75.5

Arm 1 v 2: HR 0.95
(0.80 to 1.13); arm 1 v
3: 1.05 (0.88 to 1.24)

NR
NR

52.2
63.2

18.3
23.8

RR 0.80 (0.64 to 1.00)

24.9

Arm 1 v 2: HR 0.93
NR
(0.80 to 1.07); arm 1 v 3:
0.98 (0.85 to 1.13)

26.2

Effect size
(95% CI)
HR 0.76
(0.61 to 0.96)

49

27.9

27.4

Length
(months)
41

0.05

78.9
72.9

bev=bevacizumab; D=day; HR=hazard ratio; IP=intraperitoneal; IV=intravenous; NR=not reported; RR=relative risk; taxol=paclitaxel; wks=weeks.
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regard to toxicity was higher incidence of treatment
related grade 2/3 peripheral neuropathy in the 12
cycle treatment arm (15% v 23%), although no
information was available on how long symptoms
persisted after discontinuation of treatment.
Criticisms of this trial include the allowance of
crossover and insufficient power.
GOG175 was another trial that evaluated
maintenance paclitaxel, but in an early staged
population IA or IB (grade 3 or clear cell), all stage
IC, and II EOC.77 After completion of six cycles of
carboplatin AUC6 and paclitaxel 175 mg/m2 for
three cycles, patients were randomized to either
observation or weekly paclitaxel for 24 weeks. No
differences were seen in either probability of five year
recurrence or survival.
Pazopanib, an oral, multitarget kinase inhibitor
of vascular endothelial growth factor receptors 1, 2,
and 3, platelet derived growth factor receptors α and
β, and proto-oncogene receptor tyrosine kinase, has
also been studied in this setting. The AGO-OVAR16
trial included 940 patients with stage II-IV EOC and
no evidence of progression after five or more cycles
of platinum-taxane chemotherapy, randomized
to pazopanib or placebo for up to 24 months.58
PFS, the primary endpoint, was prolonged in the
pazopanib arm (7.9 v 12.3 months; hazard ratio
0.77, 0.64 to 0.91; P=0.0021). This effect held true
regardless of BRCA status, although a more dramatic
benefit was seen among BRCA1/2 carriers. Common
adverse events associated with pazopanib included
hypertension, diarrhea, nausea, headache, fatigue,
and neutropenia.
Angiogenesis inhibition
Bevacizumab is a humanized monoclonal antibody
directed against vascular endothelial growth factor
(VEGF). Given its non-overlapping toxicity profile with
systemic chemotherapy, it is generally well tolerated,
but it does come with serious adverse effects such as
hypertension, proteinuria, hemorrhage, thrombosis,
and life threatening bowel perforation. It has been
studied in combination with chemotherapy followed
by single agent bevacizumab maintenance therapy in
two landmark trials, ICON7 and GOG0218, in the upfront setting among patients with advanced EOC.78 79
Both trials showed a modest improvement in PFS
with incorporation of concurrent and maintenance
bevacizumab compared with surveillance only. This
led to European Medicines Agency (EMA) approval
of frontline bevacizumab in the European Union in
2011, and ultimately approval by the US Food and
Drug Administration (FDA) along with maintenance
bevacizumab for advanced EOC on June 13, 2018.
However, neither ICON7 nor GOG218 showed a
difference in overall survival. A predefined subgroup
analysis of 502 patients with a poor prognosis
in ICON7 showed an overall survival benefit
among patients who received bevacizumab plus
chemotherapy compared with those who received
chemotherapy alone (restricted mean survival time
34.5 (95% confidence interval 32.0 to 37.0) months
8

with standard chemotherapy versus 39.3 (37.0 to
41.7) months with bevacizumab; log-rank P=0.03).78
High risk of progression was defined as stage IV
disease, inoperable stage III disease, or suboptimally
debulked (>1 cm) stage III disease. Although GOG218
also enrolled patients with high risk disease,
crossover to bevacizumab after progression may have
contributed to the discordance between PFS benefit
without significant improvement in overall survival.
GOG218 was unable to validate the overall survival
benefit seen in ICON7, even after classifying patients
according to ICON7 high risk criteria, but it did show
an improved PFS and overall survival specifically in
women with ascites,80 stage IV disease, or BRCA1/2
mutations or those non-BRCA1/2 carriers who were
homologous recombination deficient.79
Although studies have validated the clinical role of
VEGF inhibition, given the modest benefit in PFS to
approximately additional four months in exchange
for six cycles of concurrent therapy followed by
single agent maintenance extending beyond a year,
without objective clinical benefit on quality of life or
overall survival, this targeted management strategy
should be individualized. Reserving bevacizumab
for management of recurrent disease is reasonable
(discussed later).
Poly ADP-ribose polymerase inhibition
Other maintenance strategies after first line chemo
therapy, beyond VEGF inhibition, include PARP
inhibitors. The optimal agent in this setting remains
under investigation, but targeted therapies are
being tested in phase III clinical trials. Two PARP
inhibitors are approved by the FDA for maintenance
therapy after response to first line platinum. Olaparib
received FDA approval on the basis of SOLO-1,
a phase III randomized, double blind, placebo
controlled, multicenter trial evaluating the efficacy
and safety of olaparib as maintenance monotherapy
compared with placebo, in 391 patients with newly
diagnosed advanced BRCA mutated ovarian cancer
following platinum based chemotherapy.3 Olaparib
reduced the risk of disease progression or death by
70% (hazard ratio 0.30, 0.23 to 0.41; P<0.001), and
at 41 months’ follow-up the median PFS for patients
treated with olaparib was not reached compared
with 13.8 months for patients treated with placebo.
More recently, olaparib plus bevacizumab received
FDA approval as first line maintenance treatment
for patients with ovarian cancer who have complete
or partial response to first line platinum based
chemotherapy and whose cancer is associated with
HRD, defined by either deleterious or suspected BRCA
mutation and/or genomic instability. This expanded
indication for olaparib was based on the PAOLA-1
trial (ClinicalTrials.gov identifier NCT03737643).
This was a phase III, randomized, double blind,
placebo controlled, multicenter trial of 806 women
with stage III-IV high grade serous or endometrioid
EOC who responded to first line platinum taxane
chemotherapy plus bevacizumab. It showed a PFS
benefit of 4.5 months among patients randomized
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to olaparib plus bevacizumab maintenance versus
placebo plus bevacizumab (22.1 v 16.6 months;
hazard ratio for disease progression or death 0.59,
0.49 to 0.72; P<0.001).81 This survival benefit also
extended to patients with tumors showing HRD
regardless of BRCA status.
Veliparib (VELIA trial; NCT02470585)4 and
niraparib (PRIMA trial; NCT02655016)5 main
tenance therapy have also been studied, both
showing improvement in PFS relative to placebo in
patients with newly diagnosed advanced EOC who
respond to platinum based chemotherapy. Notable
highlights of each trial are summarized here. VELIA
randomized patients 1:1:1 to three treatment
arms—chemotherapy plus placebo followed by
placebo maintenance (control), chemotherapy
plus veliparib followed by placebo maintenance
(veliparib combination only arm), or chemotherapy
plus veliparib followed by veliparib maintenance
(veliparib throughout arm). Benefit in PFS was seen
only in the veliparib throughout cohort compared
with control (23.5 v 17.3 months; hazard ratio
0.68, 0.56 to 0.83). PRIMA, on the other hand, was
a randomized, double blind, phase III trial that
randomized 733 women 2:1 to receive niraparib or
placebo maintenance after response to platinum
based chemotherapy. Among patients with HRD,
median PFS was significantly longer in the niraparib
group compared with placebo (21.9 v 10.4 months;
hazard ratio for progression or death 0.43, 0.31 to
0.59; P<0.001). This benefit also remained when the
overall population was analyzed (13.8 v 8.2 months;
hazard ratio 0.62, 0.50 to 0.76; P<0.001). These trials
reinforce the importance of identifying a patient’s
BRCA status at the time of diagnosis. Furthermore,
the FDA approved the Myriad myChoice CDx (Myriad
Genetic Laboratories, Inc) as a companion diagnostic
for niraparib and olaparib.
Ongoing and future studies
Continuing to build on the successes of the
aforementioned trials is imperative. Ongoing
studies are exploiting shared pathways between
PARP inhibitors, antiangiogenics, and immune
checkpoint inhibitors. JAVELIN Ovarian PARP 100
(NCT03642132) was a phase III, randomized, open
label, multicenter trial investigating avelumab
in combination with and/or as a maintenance
treatment following carboplatin/paclitaxel chemo
therapy in 998 previously untreated patients with
locally advanced or metastatic EOC. At the time
of the planned interim analysis, an independent
data monitoring panel determined that neither of
the two avelumab arms would show a PFS benefit
over the control arm of chemotherapy alone.
The trial was terminated, but the investigation to
determine the optimal approach to using immune
checkpoint inhibitors in ovarian cancers is certainly
at the forefront of research. Other important research
considerations include what the optimal control arm
is and whether using adaptive platform trial designs
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is feasible in EOC trials, whereby a single protocol
simultaneously evaluates multiple treatments,
dropping arms for futility, declaring superiority of
one arm over another, or even adding new treatment
arms as the trial progresses.82
Surveillance
The SGO published a position statement for posttreatment surveillance with the goal of providing
cost effective, evidence based strategies to optimize
oncologic outcomes.83 Patients who are in complete
clinical remission after their initial treatment should
receive close surveillance follow-up every three to
four months for years 0-2, every four to six months
for years 2-3, every six months from years 3-5, and
then annually after five years. These visits should
include symptom management, examination by a
physician including a pelvic examination, and long
term wellness care. Patients should be educated
about the signs and symptoms of recurrence,
particularly pelvic pain, bloating, early satiety,
obstruction, unintentional weight loss, and fatigue.
The NCCN also recommends that referral for genetic
risk evaluation should be done if not previously
performed.
If the CA-125 concentration was initially elevated,
measurement of CA-125 or other tumor markers is
recommended during surveillance follow-up. The
sensitivity and specificity of CA-125 for detecting
recurrences range from 62% to 94% and from
91% to 100%, respectively. However, data suggest
that treating recurrence early on the basis of
detectable CA-125 concentrations in patients who
are asymptomatic may not lead to an increase in
survival and may be associated with a decreasing
quality of life.84 Supportive of this, the EORTC
conducted a randomized trial assessing the outcome
of 527 patients who were treated for recurrent EOC
based on CA-125 alone compared with clinically
evident recurrence.85 Overall survival did not differ
between the groups, and the authors concluded that
routine measurement of CA-125 is not warranted for
disease surveillance. Similarly, a post hoc analysis
of patients with recurrent, platinum resistant EOC in
the AURELIA trial showed that progression of disease
was detected earlier by imaging than by CA-125, but
this did not lead to any meaningful difference in
overall survival.86
Thus, imaging should be obtained when recur
rence is suspected and may include computed
tomography scan of the chest, abdomen, and
pelvis (sensitivity 40-93%, specificity 50-98% for
recurrent disease).87 However, given the limitations
of computed tomography scans to detect small
volume disease, other imaging modalities may be
considered, including magnetic resonance imaging
(sensitivity 62-91%, specificity 40-100%)88 or
positron emission tomography (sensitivity 45-100%,
specificity 40-100%).88-90 Ultrasonography may be
particularly useful for patients who have undergone
fertility sparing surgery.
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Recurrent ovarian cancer
Platinum sensitivity
Platinum sensitivity is generally defined as an interval
of greater than six months between the last cycle of
platinum based chemotherapy (PBC) and the start of
the subsequent course of platinum. Approximately
60-70% of patients with a platinum-free interval
(PFI) of more than 24 months will likely respond to
re-treatment with platinum. Although the way PFI
is defined varies—whether by serology only or by
radiographic findings of progressive disease—studies
have sought to test the hypothesis that prolonging
the PFI with a non-platinum agent may improve the
subsequent response to platinum.91-93 The OVA301
study is an important trial to highlight differences in
practice across the world and the practical challenges
we face for patients with partially platinum sensitive
recurrence with a PFI of six to 12 months. Although
OVA301 also included platinum resistant patients,
a post hoc analysis of 214 cases with partially
platinum sensitive relapse (PFI of 6-12 months)94
showed that the combination of trabectedin plus
pegylated liposomal doxorubicin (PLD) versus PLD
alone delayed subsequent platinum treatment by 2.5
months and led to an improved PFS (7.4 v 5.5 months;
hazard ratio 0.65; P=0.015) and a 41% decrease in
the risk of death (overall survival 23 v 17.1 months;
hazard ratio 0.59; P=0.0015).95 On the basis of these
results, trabectedin-PLD combination was approved
in the European Union for patients with platinum
sensitive recurrent EOC, but the US FDA required
additional data to support the combination. The
final overall survival analysis of 672 women (522
deaths) did not meet the protocol defined criterion
for statistical significance (95% confidence interval
0.72 to 1.02; P=0.0835).96 The study was originally
powered to detect a 33% increase in overall survival.
Of note, an unexpected imbalance of PFI was seen,
favoring the PLD arm. An ad hoc prognostic factor
adjusted analysis of overall survival suggested that a
benefit might have been seen in patients treated with
trebectedin-PLD if the PFI were balanced between
study arms. INOVATYON, a prospective phase III trial
comparing trabectedin-PLD followed by platinum
versus PBC (NCT01379989), has completed accrual,
and we are currently awaiting trial results.
Results from MITO8 are consistent with the final
analysis of OVA301 and call into question whether
a survival benefit is gained by extending the PFI
among patients with partially platinum sensitive
EOC that recurs after six to 12 months.97 This was
an international, multicenter, open label phase
III randomized controlled trial in 215 patients,
comparing non-platinum based chemotherapy
(NPBC) followed by PBC at subsequent relapse
with the standard sequence of PBC followed by
NPBC.97 NPBC was PLD in more than 85% of cases.
PFI was prolonged in the experimental arm (7.8 v
0.01 months), but no overall survival benefit was
seen, and quality of life was significantly worse
in the experimental arm. The meaning of PFI only
becomes more convoluted when we consider the
10

current era of maintenance therapies after first
line treatment, including PARP inhibitors and
bevacizumab.
Surgery for recurrent ovarian cancer
Recent data on the role of secondary cytoreductive
surgery from prospective randomized trials have filled
a gap in the literature in an era when maintenance
therapy with bevacizumab, PARP inhibitors, or both is
quickly becoming a mainstream strategy with proven
PFS benefit among patients with platinum sensitive,
recurrent disease. GOG213 was an open label,
phase III, multicenter, international, randomized
clinical trial of 485 patients with platinum sensitive,
recurrent EOC who had received one previous therapy
and whose disease the investigator determined to be
resectable.98 Women were randomized 1:1 either to
secondary surgical cytoreductive surgery followed
by adjuvant PBC or to receive PBC alone. Choice of
adjuvant chemotherapy (paclitaxel-carboplatin or
gemcitabine-carboplatin) and bevacizumab was left
to the treating physician. With regard to the primary
endpoint, the study showed that secondary surgical
cytoreduction followed by chemotherapy did not
result in longer overall survival than chemotherapy
alone (median overall survival 50.6 v 64.7 months;
hazard ratio for death 1.29, 0.97 to 1.72; P=0.08).
This effect was not altered after adjustment for PFI
and chemotherapy choice. Median PFS was 18.9
months and 16.2 months, and the hazard ratio for
disease progression or death was 0.82 (0.66 to 1.01).
As highlighted in the authors’ discussion, dilution
of an independent surgical effect could be due to
selection bias of patients who were considered to
have “substantial platinum-sensitivity” with a
median PFI of 20.4 months and relatively limited
tumor volume, with more than half having two or
fewer sites of recurrence.
Two phase III randomized clinical trials
are evaluating this clinical question: an
Arbeitsgemeinschaft Gynaekologische Onkologie
(AGO) trial entitled Descriptive Evaluation of
Preoperative Selection Criteria for Operability in
Recurrent EOC (DESKTOP) III (NCT01166737) and
Surgery or Chemotherapy in Recurrent Ovarian
Cancer (SOC 1; NCT01611766). The Netherlands
SOCceR trial (NTR3337) recently closed to accrual,
and we anxiously await the results. Presented as an
abstract at the ASCO meeting in 2017, preliminary
results from DESKTOP III suggested a PFS benefit of
5.6 months (19.6 v 14.0 months; P<0.001) and longer
time to the start of subsequent chemotherapy (21.0 v
13.9 months; P<0.001) among women with platinum
sensitive recurrent EOC who underwent secondary
cytoreduction versus a platinum containing second
line therapy. The primary endpoint of overall survival
is still not mature.99 The most notable differences
between GOG213 and DESKTOP III lay in the patient
selection criteria and adjuvant therapy, particularly
the rate of maintenance bevacizumab (84% and
20%, respectively). Taken together, maturity of
data from DESKTOP III and the other two trials will
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Table 4 | Landmark chemotherapy trials in platinum sensitive recurrent ovarian cancer
Progression-free survival
Study
ICON4100

Primary
outcome
OS

AGO101

PFS

CALYPSO102

PFS

OCEANS103

PFS

GOG 213104*

PFS

AGO-OVA 2.21/
ENGOT105

PFS

Study groups
Carbo
Carbo/taxol
Carbo
Carbo/gem
Carbo/taxol
Carbo/PLD
Carbo/gem/placebo
Carbo/gem/bev
Carbo/taxol
Carbo/taxol/bev + bev maintenance
Carbo/gem/bev + bev maintenance
Carbo/PLD/bev + bev maintenance

Length
(months)
10
13
5.8
8.6
9.4
11.3
8.4
12.4
10.4
13.8
11.7
13.3

Hazard ratio
(95% CI)
0.76 (0.66 to 0.89)

P value
0.0004

0.72 (0.58 to 0.90)

0.003

0.82 (0.72 to 0.94)

0.005

0.48 (0.39 to 0.61)

<0.0001

0.63 (0.53 to 0.74)

<0.001

0.80 (0.68 to 0.96)

0.013

Overall survival
Length
(months)
24
29
17.3
18.0
30.7
33.0
32.9
33.6
37.3
42.2
NR
NR

Hazard ratio (95% CI)
0.82 (0.69 to 0.97)

P value
0.02

0.96 (0.75 to 1.23)

0.73

0.99 (0.85 to 1.16)

0.94

0.95 (0.77 to 1.17)

0.65

0.83 (0.68 to 1.01)

0.06

NR

NR

bev=bevacizumab; Carbo=carboplatin; gem=gemcitabine; NR=not reported; PLD=pegylated liposomal doxorubicin.
*OS based on audited treatment-free interval stratification data: hazard ratio 0.823 (0.68 to 0.996); P=0.0447.

hopefully bring clarity to the value of surgery in this
patient population.
Platinum sensitive recurrence
Platinum based chemotherapy for recurrent disease
Individualization of management strategies should
consider previous tolerance of chemotherapy,
residual symptoms, and current performance status.
We recognize that not all patients are candidates for
platinum doublets, but the modest PFS benefit of
combination therapy compared with single agent
platinum should be factored into the shared decision
making. Table 4 lists landmark trials that have helped
to shape the landscape of chemotherapy for patients
with recurrent, platinum sensitive EOC.100-105
ICON4/OVAR2.2 was the first phase III randomized
controlled trial comparing platinum monotherapy
with platinum and paclitaxel therapy in women with
relapsed EOC.100 The benefit in overall survival (29
v 24 months; hazard ratio 0.82; P=0.02) and PFS
(12 v 9 months; 0.76; P<0.001) with combination
therapy set the stage for future trials that often use
the platinum-taxane combination as a reference
group. This finding was also confirmed in a metaanalysis, which showed that combination PBC was
associated with improved overall survival (hazard
ratio 0.80; P=0.05) and PFS (0.68; P<0.001).106
Separate subgroups analysis defined by previous
paclitaxel exposure, PFI (6-12 v 12 months), or
number of previous lines of chemotherapy did not
show a difference in the relative effect of combination
chemotherapy on either PFS or overall survival.
Subsequent trials aimed to study different platinum
combinations that would confer survival benefit
while minimizing toxicities. A phase III randomized
controlled trial showed that the combination of
gemcitabine plus carboplatin versus carboplatin
improved PFS by 2.8 months (8.6 v 5.8 months;
hazard ratio 0.72; P=0.003), with no difference in
overall survival and increased myelosuppression
(70% had grade 3-4 neutropenia and 35% had
grade 3-4 thrombocytopenia).101 Similarly, the noninferiority randomized controlled trial CALYPSO
showed that carboplatin and PLD compared with
the bmj | BMJ 2020;371:m3773 | doi: 10.1136/bmj.m3773

carboplatin and paclitaxel improved median PFS
(11.3 v 9.4 months; hazard ratio 0.82; P=0.005)
without an overall survival benefit (hazard ratio
0.99; P=0.87) at the expense of increased hand-foot
syndrome (12.0% v 2.2%), nausea (35.2% v 24.2%),
and mucositis (13.9% v 7%).102 107

Bevacizumab
Bevacizumab has been studied extensively in patients
with platinum sensitive tumors, in combination
with chemotherapy and followed by single agent
maintenance therapy—OCEANS, GOG213, and AGOOVAR2.21 (table 4). The prolongation in PFS by four
months in this setting is what led to approval by the
US FDA and the EMA for the treatment of platinum
sensitive, recurrent EOC.
One of the more practical challenges that oncologists
face is whether to re-treat with bevacizumab in
a patient with platinum sensitive EOC who has
already received bevacizumab as part of the first line
treatment of her disease. Presented in abstract form
at ASCO’s 2018 annual meeting, MITO16B-MaNGO
OV2B-ENGOT OV17 (NCT01802749) considered this
question and showed a prolongation of PFS by three
months (11.8 v 8.8 months; hazard ratio 0.51, 0.41
to 0.64; P<0.001) in patients with platinum sensitive,
recurrent EOC re-treated with bevacizumab plus
concomitant second line chemotherapy (carboplatinpaclitaxel, carboplatin-gemcitabine, or carboplatinPLD) followed by bevacizumab maintenance
compared with platinum doublet chemotherapy
alone.108 Median overall survival was 27.1 months
and 26.7 months without and with bevacizumab
(hazard ratio 1.00, 0.73 to 1.39; P=0.98), with no
unexpected toxicity.
PARP inhibitors
Both the FDA and EMA have approved three different
PARP inhibitors to expand the armamentarium
of targeted therapeutics for patients with EOC
(table 5). PARP inhibitors were first approved for
use as single agents in patients with recurrent
EOC with deleterious germline or somatic BRCA
mutations who had not responded to previous lines
11
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of chemotherapy. However, the substantial PFS
advantage that is sustained with maintenance PARP
inhibition after response to PBC has made them the
preferred strategy in this setting, especially among
patients who harbor a germline or somatic BRCA
mutation. This benefit has also extended to those
who have HRD and, although to a lesser degree, to
patients with BRCA wild-type and even to patients
who have residual disease after responding to PBC.
However, a benefit in overall survival has not yet
been shown owing to the need for longer follow-up.
A practical dilemma that we will be faced with is
the management strategy to treat patients who have
recurrent platinum sensitive ovarian cancer and
have been previously treated with frontline PARP
maintenance. In this situation, enrolling the patient
in a clinical trial would be the first recommendation,
but inevitability oncologists will be faced with the
decision between maintenance bevacizumab and rechallenge with PARP inhibitor. For the latter, whether
the PARP inhibitor should be the same as the one used
previously or a different brand remains unclear. An
abstract presented at the 2019 SGO annual meeting
described a retrospective, multi-institutional study
of 22 patients with EOC that investigated previous
exposure to PARP inhibitor.109 Treatment with a
second PARP inhibitor most often involved niraparib
(10; 45%), olaparib (6; 27%), or rucaparib (6; 27%),
with none using veliparib, and the most common
reason for discontinuing treatment was progression
(13; 59%) followed by toxicity (6; 27%). Until more
research is forthcoming, selection of maintenance
therapy should be based on considerations of current
and potential toxicities related to each therapy as
well as response to previous therapies. Mechanisms
of resistance to PARP inhibitors and prediction of
resistance are important areas of ongoing research.
Four randomized phase III trials have reported
their outcomes on PARP inhibitor maintenance for
patients with platinum sensitive, recurrent EOC
(table 6), all supporting the clinical benefit of using
PARP inhibitors as maintenance therapy for those
who are responding to PBC.6 110-112 NOVA and ARIEL3
extended their inclusion criteria to encompass
patients regardless of their BRCA status and
investigated the impact of other biomarkers, such as
loss of heterozygosity/homologous recombination

status, to predict response to treatment.111 112 Other
notable discrepancies related to the inclusion criteria
are BRCA mutation status and amount of residual
disease allowed. Furthermore, even though PFS was
consistently chosen as the primary outcome, the
method of assessment differed between studies—all
but STUDY19 used investigator assessed PFS only.6

Future directions for PARP inhibitors
The current landscape of trials for platinum sensitive
recurrent EOC is exciting and quickly expanding,
with trials that are investing not only the role of
PARP inhibitors in combination with antiangiogenic
agents or immune checkpoint inhibition (discussed
below) but also the concept of PARP inhibitor
maintenance retreatment. Combining molecular
targeted therapies for women with platinum
sensitive recurrent EOC, particularly for those who
lack a known BRCA mutation, is another important
area of research. A randomized, phase II trial of
90 women with measurable, platinum sensitive
recurrent EOC showed that the combination of
olaparib with cediranib versus olaparib alone
significantly improved median overall response
rate (ORR) by 32% and median PFS by 8.7 months
(17.7 v 9.0 months; hazard ratio 0.42, 0.23 to 0.76;
P=0.005).113 As expected, grade 3-4 adverse events
were more common with the combination therapy,
including fatigue (27% v 11%), diarrhea (23% v
0%), and hypertension (39% v 0%). Subset analysis
showed significant benefit on PFS in gBRCA wildtype/unknown patients receiving olaparib-cediranib
compared with olaparib alone (16.5 v 5.7 months;
P=0.008). More recently, a press release from
AstraZeneca and Merck reported that the addition of
cediranib to olaparib did not result in improved PFS
in comparison with PBC in patients with platinum
sensitive recurrent EOC, which was the primary
endpoint of the phase III NRG-GY0004 trial.114
Phase II AVANOVA (NCT02354131) will randomize
patients with platinum sensitive recurrent EOC to
either niraparib or niraparib plus bevacizumab.
Other current research initiatives are studying the
role of PARP inhibitors after exposure to initial PARP
inhibitors used upfront as first line maintenance
therapy. The MOLTO (Multi-maintenance Olaparib
After Disease Recurrence in Participants With

Table 5 | Poly ADP-ribose polymerase (PARP) inhibitors for patients with epithelial ovarian cancer (EOC)
Drug
Olaparib

Rucaparib

Niraparib

Time of approval
December 2018
August 2017

Agency
FDA

February 2018
December 2016
April 2018
May 2018
Jan 2019
March 2017
September 2017

EMA
FDA
EMA
FDA
EMA

Indications
Advanced EOC, post CR/PR to platinum based chemotherapy
Advanced EOC
Platinum sensitive recurrent OC, post CR/PR
Platinum sensitive recurrent HGOC, post CR/PR
Advanced OC
Platinum sensitive recurrent OC, post CR/PR
Platinum sensitive recurrent or progressive HGOC
Platinum sensitive recurrent OC, post CR/PR
Platinum sensitive recurrent OC, post CR/PR
Platinum sensitive recurrent HGSOC, post CR/PR

BRCA status
g/sBRCA
gBRCA
g/sBRCA
g/sBRCA
-

Clinical setting
First line maintenance
Monotherapy, fourth line
Maintenance
Maintenance
Monotherapy, third line
Maintenance
Monotherapy, third line
Maintenance
Maintenance
Maintenance

Dosing
300 mg BID

600 mg BID

300 mg QD

BID=twice daily; BRCA=breast cancer susceptibility gene; CR/PR=complete response or partial response; EMA=European Medicine Agency; FDA=Food and Drug Administration; g/
sBRCA=germline and/or somatic BRCA1/2 mutation; HGOC=high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer; HGSOC=high grade serous epithelial ovarian, fallopian
tube, or primary peritoneal cancer; OC=epithelial ovarian, fallopian tube, or primary peritoneal cancer; QD=once daily.
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Table 6 | Poly ADP-ribose polymerase (PARP) inhibitor maintenance for patients with platinum sensitive, recurrent ovarian cancer
Rucaparib

Niraparib

STUDY196

Olaparib
SOLO2110

ARIEL3111

NOVA112

265
Platinum sensitive recurrent
HGSOC; PR/CR after ≥2 previous
lines of PBC
gBRCA; sBRCA; BRCAwt
1:1
Olaparib 400 mg BID (capsules)
v placebo
Investigator assessed PFS

295
Platinum sensitive recurrent HGS
or endometrioid OC; PR/CR after ≥2
previous lines of PBC
gBRCA; sBRCA
2:1
Olaparib 300 mg BID
(tablets) v placebo
Investigator assessed PFS

564
Platinum sensitive recurrent HGS or
endometrioid OC; PR/CR after ≥2 previous
lines of PBC ≥2 previous lines of PBC
gBRCA; sBRCA; BRCAwt
FoundationFocus CDxBRCA LOH
2:1
Rucaparib 600 mg BID v placebo

553
Platinum sensitive HGSOC; PR/
CR after ≥2 previous lines of PBC

QOL assessment
Results
PFS g/sBRCAm

FACT-O; FOSI

FACT-O; EQ-5D-5L

NFOSI-18; DRS-P

-

PFS gBRCAwt

-

16.6 v.5.4 months; HR 0.23
(0.16 to 0.34); P<0.001
-

PFS HRD or LOH high

-

19.1 v 5.5 months; HR 0.30
(95% CI 0.22 to 0.41); P<0.001
7.4 v 5.5 months; HR 0.54
(0.34 to 0.85); P=0.0075
NA

PFS HRP or LOH low

-

NA

Toxicities (%)
Dose reduction
Drug discontinued
Any grade >3 AE*
Anemia
Neutropenia
Thrombocytopenia
Nausea
Fatigue

-

25
11
36
25
20
34
3
8

Design
No of patients
Population
Eligible BRCA status
HRD assessment
Randomization
Intervention
Primary endpoint

Investigator assessed PFS

gBRCA; sBRCA; BRCAwt
myChoice HRD
2:1
Niraparib 300 mg daily v
placebo
Investigator assessed PFS
and PFS by BICR
FOSI; EQ-5D-5L

9.7 v 5.4 months*; HR 0.44
(0.29 to 0.66); P<0.001
6.7 v 5.4 months*; HR 0.58
(0.40 to 0.85); P=0.0049

21.0 v. 5.5 months; HR 0.27
(0.17 to 0.41); P<0.001
9.3 v 3.9 months; 0.45
(0.34 to 0.61); <0.001
12.9 v 3.8 months; HR 0.38
(0.24 to 0.59);P<0.001
6.9 v 3.8 months; HR 0.58
(0.36 to 0.92); P=0.02

55
13
36
19
7
5
4
7

66
14
36
25
20
34
3
8

AE=adverse event; BICR=blinded independent central review; BID=twice daily; BRCA=breast cancer susceptibility gene; BRCAwt=BRCA wild-type; g/sBRCAm=germline and/or somatic BRCA1/2
mutation; DRS-P=disease related symptoms-physical; FACT-O=Functional Assessment of Cancer Therapy-Ovarian; FOSI=FACT/NCCN Ovarian Symptom Index; HR=hazard ratio; HRD=homologous
recombination deficient/deficiency; HGS=high grade serious; HRP=homologous recombination proficient LOH=loss of heterozygosity; NFOSI-18=NCCN/FACT Ovarian Symptom Index (subset of
FACT-O); OC=epithelial ovarian, fallopian tube, or primary peritoneal cancer; mo= months; PBC=platinum based chemotherapy; PFS=progression-free survival; QD=once daily; QOL=quality of life.
*Exploratory subgroup analyses.

Platinum-Sensitive BRCA mutated High Grade Serous
Ovarian Cancer) study (NCT02855697) is a phase I
study that includes BRCA1/2 patients, and OREO
(Olaparib Maintenance Retreatment in Patients
with Epithelial Ovarian Cancer) is a phase III study
(NCT03106987) involving patients with and without
BRCA mutations.
Platinum resistant recurrence
Platinum resistant EOC is defined as recurrence of
disease within six months of completion of surgery
and adjuvant chemotherapy. Platinum resistance
generally portends a very poor prognosis, with
overall survival rates from the time of diagnosis of
resistant disease of only 12-14 months. Discussions
about goals of care and quality of life, essential to
any cancer discussion, are critical at this junction
as this class of ovarian cancer is almost uniformly
incurable. Surgery is almost always avoided in this
patient population, although some exceptions may
exist.

Monotherapy strategies
Monotherapy for platinum resistant disease achieves
minimal responses of the order of 10-20%. Single
agent therapy includes weekly paclitaxel with a
response rate of up to a 21% in a phase II clinical
the bmj | BMJ 2020;371:m3773 | doi: 10.1136/bmj.m3773

trial, with minimal grade 3-4 side effects.115 Another
phase III trial compared the use of topotecan with
PLD every 28 days and found similar response rates
and overall survival (up to 13 months) with less
toxicity in the PLD arm.116 117

Angiogenesis therapy
In an attempt to enhance these response rates,
the addition of bevacizumab to these three agents
(topotecan, taxol, and PLD) was examined in a
large phase III trial, AURELIA. Nearly 400 patients
were randomized to single agent therapy with the
aforementioned drugs or doublet therapy with the
addition of bevacizumab. Inclusion criteria were
very specific to exclude previous anti-angiogenesis
treatment, bowel obstruction, or more than two
previous lines of treatment. Outcomes showed
improved an ORR of 31%, improved PFS (6.7
months), and generally good tolerability with the
addition of bevacizumab. A subset analysis showed
that weekly paclitaxel with bevacizumab (ORR
53%) may offer the best benefit compared with
the other doublet regimens, although it requires
weekly infusions. No overall survival advantage was
seen with the addition of bevacizumab. Another
regimen to consider is cisplatin/gemcitabine plus
bevacizumab, which was examined in a phase II
13
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clinical trial of both platinum resistant and platinum
sensitive patients (n=35).118 Interestingly, although
numbers were small, a 78% complete and partial
response rate was seen although 29% experienced
grade 3-4 neutropenia. Given the incurable nature
of this disease, management options for most
patients are often based on ongoing toxicities and
the potential impact of future treatments on quality
of life. Incorporation of bevacizumab is a reasonable
option on the basis of the AURELIA trial, knowing
that the ideal candidate is one who has received
fewer than two previous regimens, has no previous
exposure to bevacizumab, and has no history of a
bowel obstruction in the previous six months (or no
evidence of malignant bowel involvement).
The use of immunotherapy (discussed in detail
below) and PARP therapy presents a potential new
frontier in the treatment of platinum resistant EOC.
The results of the phase II TOPACIO/KEYNOTE-162
trial showed that 300 mg of daily niraparib orally
with 200 mg of intravenous pembrolizumab every 21
days had a 13% and 47% partial and stable response
rate, respectively.119 The disease control rate of 65%
was impressive in this cohort of platinum resistant
patients. The QUADRA study evaluated the efficacy
of single agent niraparib at 300 mg daily in a heavily
pretreated group (three or more previous lines of
chemotherapy) of patients with recurrent EOC.120
A total of 463 patients were enrolled, of whom
151 (33%) had platinum resistant disease and 161
(35%) were refractory to platinum. ORR was as high
as 28%, with a low complication rate globally. Given
that quality of life is of paramount importance, the
use of an oral agent to obtain treatment response is
important in this group.
Another notable trial for this specific population
is the randomized, open label, phase III JAVELIN
Ovarian 200 trial presented at the 2019 SGO Annual
Meeting on Women’s Cancer. Avelumab alone or in
combination with pegylated liposomal doxorubicin
did not meet its primary objectives of significantly
improving PFS or overall survival among patients
with platinum resistant or refractory EOC. However,
the planned subgroup analysis suggested that
patients with PD-L1 positive tumors (58% of
patients) had improved PFS (3.7 v 1.9 months) and
improved overall survival (18.4 v 13.8 months) for
avelumab-PLD versus PLD.
Emerging and novel therapies
Immunotherapy
Immunotherapy presents a potentially novel
frontier in the treatment of recurrent EOC. Immune
checkpoints are regulators of the immune system,
intended to maintain self-tolerance and prevent
autoimmunity. However, some cancers can protect
themselves from immune attack by stimulating
immune checkpoint targets. Studies have shown
the efficacy of immune based therapies with
improved survival in a host of cancers including
metastatic melanoma, renal cell carcinoma, and
lung cancer.121-123 In particular, the association of
14

intratumoral tumor infiltrating lymphocytes and
improved clinical outcomes for EOC patients suggests
that this tumor type is potentially immunoreactive,
but preliminary trials have shown mixed results with
regard to the efficacy of these modalities.
Given that this is an evolving area of active
research, we highlight here only a few studies
involving the combination of checkpoint inhibitors
with PARP inhibitors, bevacizumab, or both. The
basis of studying such combinations stems from
mouse models that have shown that PARP inhibitors
can activate interferon signaling and synergize
with programmed cell death 1 (PD-1) or cytotoxic
T lymphocyte associated protein-4 (CTLA-4)
blockade.124 Translating this to early phase clinical
trials, the MEDIOLA study was presented as a late
breaking abstract at SGO 2018. It was an open label,
phase II basket study of durvalumab (anti-PD-L1) in
combination with olaparib, studied in 32 patients
with platinum sensitive recurrent BRCA mutated
tumors and resulted in an ORR of 72%, including a
complete response rate of 19%.125 Among patients
with BRCA wild-type tumors, the combination
resulted in an ORR of 17% and a disease control rate
of 83% at six months. Overall, it was well tolerated,
although the most frequent grade 3 or higher adverse
events were anemia (12%) and increased lipase (9%);
the most common immune related adverse events (all
grades) were hypothyroidism (15%) and rash (12%).
As mentioned above, results from the phase I/II
TOPACIO/KEYNOTE-162 trial confirmed tolerability
and antitumor activity in recurrent EOC patients with
the combination of the PARP inhibitor niraparib with
an anti-PD-1 antibody, pembrolizumab.119
A recent phase II trial of 38 patients has shown the
efficacy of combining a PD-1 inhibitor, nivolumab,
with bevacizumab and showed a 40% ORR in patients
with platinum sensitive tumors and mean PFS of 12.1
months.126 Of note, a phase II study of nivolumab
monotherapy found a 15% ORR in patients with
platinum resistant disease, with a mean PFS of 3.5
months and overall survival of 20 months.127 Other
combination immunotherapies such as nivolumab
with the CTLA–4 targeted therapy ipilimumab have
shown up to 31% ORR and a hazard ratio of 0.59 for PFS
in patients with platinum sensitive, recurrent EOC.128
Folate receptor antibody drug conjugates
Folate receptor antibody drug conjugates such as
mirvetuxumab soravtansine are another potential
avenue to therapy in patients with platinum resistant,
recurrent ovarian cancer. This was explored in a phase
IB trial of 66 patients treated with mirvetuxumab and
bevacizumab.129 The objective response rate of 39%
and mean PFS of 6.8 months showed substantial
promise for the use of this doublet combination in a
heavily pretreated recurrent population. Ocular side
effects such as blurred vision as well as keratopathy
must be managed by proactive mitigation strategies
(for example, lubricating and steroid eye drops)
and patients must be followed closely for long-term
ocular sequelae.
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Mismatch repair and microsatellite instability in
ovarian cancers
Testing for microsatellite instability and defects
in mismatch repair is increasingly being used to
identify point mutations that may offer targeted
therapies in ovarian cancer. Defects in mismatch
repair substantially increase the risk of developing
ovarian cancer as part of hereditary cancer
syndromes such as hereditary non-polyposis
colorectal cancer. Identification of these defects
in ovarian cancer patients is important both for
genetic testing of family members and for the use
of novel therapies. New data suggest that mismatch
repair deficient and microsatellite instability-H
ovarian cancer tumors may predict responsiveness
to anti-PDL-1 immunotherapy agents such as
pembrolizumab.130 The KEYNOTE-028 trial showed
that in a subset of PDL-1 positive patients with
EOC, pembrolizumab conferred durable antitumor
activity with manageable safety and toxicity.131 Use
of molecular markers such as MSI-H and PDL-1 is
thus important in the armamentarium of targeted
therapies in ovarian cancer.
Chimeric antigen receptor therapy
CAR-T in EOC is a potentially novel way to fight
metastatic ovarian cancer. CAR-T is a complicated
and expensive process that has shown promise
in killing cancer cells in a host of disease sites. It
involves extraction of host T cells and use of gene
editing to induce these cells to express chimeric
antibodies on the cell surface, which then go and
attach to cancer cells in the host when reintroduced.
This type of therapy has shown promise mainly in
blood malignancies, but a potentially significant
application exists in solid tumors such as ovarian
cancer. This is because ovarian cancer cells overexpress MUC 16, which allows them to escape
immune surveillance by host defense systems. A
preliminary paper in Nature BME reported efficacy
in tumor reduction in mouse models of ovarian
cancer.132 Although these data are promising, CAR-T
remains in its infancy for treatment of EOC.
Quality of life and palliative care
Providing comprehensive cancer care is a commitment
to recognizing that cancer care is a lifelong journey,
exposing many patients to a multitude of relapses
and treatment related adverse events that have the
potential to negatively affect quality of life. The NCCN
has guidelines to help oncology providers to optimize
symptom management early in the disease process
and feel comfortable discussing goals of care so that
they align with the values, beliefs, and cultures of
their patients as well as patients’ families and care
givers.133 The goal of palliative care is to anticipate,
prevent, and reduce suffering and to support the best
possible quality of life, regardless of cancer stage or
need for additional therapies. When integrated early,
palliative care has been shown to have a profound
effect on quality of life while reducing symptom
intensity, particularly among patients with advanced
the bmj | BMJ 2020;371:m3773 | doi: 10.1136/bmj.m3773

cancer.134 Over the past 20 years, palliative care has
developed into an integral part of comprehensive care,
with the goal of early intervention to optimize quality
of life with potential to improve survival outcomes as
well.135 136 Importantly, this advancement in clinical
care is equally matched by robust efforts in the
research arena, as ongoing efforts are being made to
integrate patient centered outcomes in clinical trial
designs. Although palliative care should be started
early in the disease process to optimize quality of
life, we acknowledge that it becomes the primary
focus of care when disease directed, life prolonging
therapies are no longer effective or desired. Shared
decision making between patients and oncologists
is critical when selecting next treatment strategies,
ensuring that these discussions include acceptable
safety profile, balance symptom benefit with risks,
and achieve a common goal.
Guidelines
The NCCN guidelines serve as internationally
accepted standards to help to improve high quality,
high value cancer care worldwide. The NCCN has
an active presence in Europe, including more than
140 000 registered European users and almost
720 000 NCCN Clinical Practice Guidelines in
Oncology (NCCN guidelines) downloaded in 2018.137
The guidelines panel consists of members only from
the US, but evidence based practices for ovarian
cancer management stem from large, multicenter
trials that have been conducted both in the US
and internationally. Although NCCN guidelines
are consistent with European Society for Medical
Oncology guidelines, the section “Principles of
systemic therapy” reflects specific therapeutic agents
that are based on US FDA approval. Specific to the
material covered in this review, we have highlighted
some differences in indication and approval dates for
PARP inhibitors.
The Journal of Clinical Oncology recently published
a special issue devoted to summarizing the most
important developments in treating gynecologic
cancers.138 Invited authors included both US and
internationally renowned oncologists who shared
evidence based practices that have been widely
adopted to achieve improved outcomes of women
with gynecologic malignancies. We used this series
of articles as a foundation for this review and made
sure to site all relevant articles on ovarian cancer
management.
Conclusions
EOC remains the most lethal gynecologic cancer,
with most women presenting with advanced stage
disease and five year survival rates approximating
48%.2 Surgical cytoreduction is a strong predictor
of prognosis, as a direct correlation exists between
the extent of postsurgical tumor residuum and
progression-free and overall survival.38 39 PCS
followed by platinum based chemotherapy remains
the standard treatment for patients with advanced
stage EOC, but neoadjuvant chemotherapy may
15
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be considered for patients who are not likely
to achieve optimal cytoreduction or who are
poor surgical candidates.30 Research on first
line treatment has focused on optimization of
conventional chemotherapy with platinum/taxane
doublet (for example, dose intensity, dose density,
and incorporation of different agents, as well as
intraperitoneal drug administration) and extended
maintenance with cytotoxic chemotherapy during
remission. Despite these advances, most patients
with advanced stage disease experience relapse, and
the likelihood of responding to subsequent courses
of platinum based chemotherapy greatly depends
on the platinum-free interval. Fortunately, advances
in multiplex panels for cancer susceptibility for
both germline and somatic mutations have led to
several management strategies that have changed
practice: universal genetic screening for all women
with newly diagnosed EOC; targeted therapies such
as bevacizumab and/or PARP inhibitors for first
line maintenance therapy; and PARP inhibitor as
monotherapy in the recurrent setting. Nevertheless,
a greater understanding of the molecular landscape
of EOC is needed to improve survival outcomes,
especially for rare chemotherapy resistant histo
logies. Immediate research priorities should be
aimed at developing robust clinical trials that
test novel, targeted therapies that are supported
by predictive biomarkers, integrate evaluation of
mechanisms of sensitivity and resistance,139 and
incorporate patient centered outcomes and quality of
life measures.

Questions for future research

• What are the biomarkers that predict improved
treatment responses in advanced ovarian cancer (PDL1, PD-1, CTLA-4, etc)?
• What genetic aberrations occur to incite
carcinogenesis in wild-type (non-BRCA mutated)
ovarian cancer and how can these be detected
earlier?
• Can the immune microenvironment be modulated to
better potentiate treatments for ovarian cancer?

Patient involvement

A patient with advanced ovarian cancer, who is a PhD
nurse scientist, assisted in answering questions about
what issues are of concern to her as an ovarian cancer
survivor. The patient raised issues revolving around
palliative care and novel therapies
Contributors: LK and SRG contributed equally to the design,
development, and writing of this manuscript and guarantee
authenticity of its authorship.
Competing interests: We have read and understood the BMJ policy
on declaration of interests and declare the following interests: SRG
has participated in advisory boards for AstraZeneca and Clovis
Oncology.
Provenance and peer review: Commissioned; externally peer
reviewed.
1
2
3

Glossary of abbreviations

• ASCO—American Society of Clinical Oncology
• CA-125—cancer antigen 125
• CAR-T—chimeric antigen receptor therapy
• CTLA-4—cytotoxic T lymphocyte associated protein-4
• EMA—European Medicines Agency
• EOC—epithelial ovarian cancer
• EORTC—European Organization for Research and
Treatment of Cancer
• FDA—Food and Drug Administration
• HGSOC—high grade serous ovarian cancer
• HIPEC—heated intraperitoneal chemotherapy
• HRD—homologous recombination deficiency
• ICS—interval cytoreductive surgery
• NCCN—National Comprehensive Cancer Network
• NPBC—non-platinum based chemotherapy
• ORR—overall response rate
• PARP—poly ADP-ribose polymerase
• PBC—platinum based chemotherapy
• PCS—primary cytoreductive surgery
• PD-1—programmed cell death 1
• PFI—platinum-free interval
• PFS—progression-free survival
• PLD—pegylated liposomal doxorubicin
• RFS—recurrence-free survival
• SGO—Society of Gynecologic Oncology
• VEGF—vascular endothelial growth factor
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